Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Barrett, Claire https://orcid.org/0000-0002-0362-0382
Hirano, Yuji https://orcid.org/0000-0002-0422-8139
Ikeda, Kei https://orcid.org/0000-0003-0574-9611
Paizis, Kathy https://orcid.org/0000-0002-3580-1970
Sameshima, Azusa https://orcid.org/0000-0002-8087-6066
Mountian, Irina https://orcid.org/0000-0002-1510-6428
Wong, Priscilla C. https://orcid.org/0000-0001-8713-9539
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 5 July 2022
Accepted: 1 September 2022
First Online: 26 September 2022
Declarations
:
: Y. Tanaka: Speakers’ fees and/or honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, GSK, Mitsubishi-Tanabe and Pfizer; Research grants from AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Daiichi-Sankyo, Eisai and Takeda. C. Barrett: President of Australian Rheumatology Association (since May 2022). Y. Hirano: None. K. Ikeda: Speakers’ fees and/or honoraria from AbbVie, Asahi-Kasei, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe, Novartis, Pfizer, UCB; Research grants from Mitsubishi-Tanabe. K. Paizis: Speakers’ fees and/or honoraria from Praxhub. A. Sameshima: Speakers’ fees and/or honoraria from Astellas, Mitsubishi-Tanabe and UCB. I. Mountian: Employee and shareholder of UCB Pharma. P. Wong: None.
: Since this was a market research study, prior approval of the protocol by an ethics committee was not required. As both market research companies involved are based in Australia, the study was conducted in accordance with Australian market research guidelines, including the obtaining of informed consent and adherence to ethical reporting standards.
